Arthneeti
All Q4 FY26 results →
SA

Solara Active Pharma Sciences Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Solara Active Pharma Sciences Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹617
Market cap₹2.4K Cr
P/E573.4
Updated23 Aug 2026
Read4 min read

The short version

The company expects growth momentum mainly from its base business, focusing on expanding existing products and customers rather than ibuprofen or CRAMS, which remain subscale. The company does not provide explicit future earnings or EPS guidance but expresses optimism about sustaining and improving current performance.

From Solara Active Pharma Sciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company expects growth momentum mainly from its base business, focusing on expanding existing products and customers rather than ibuprofen or CRAMS, which remain subscale.
  • New product filings through R&D (4-5 DMFs annually) will start contributing around FY29-FY30, driving medium- to long-term growth.
  • Incremental revenue growth will be supported by better operational efficiency, yield improvement, and capacity debottlenecking within existing facilities (around 30% spare capacity available).
  • The company prefers investing resources in high-margin base business rather than commodity segments like ibuprofen, which have shown negative returns.

2 more points from Solara Active Pharma Sciences Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Solara Active Pharma Sciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • No large greenfield capex planned; focus is on utilizing existing capacity (around 30% spare capacity available).
  • Incremental capex being done to debottleneck lines for high-margin products and improve cycle times.
  • No big capex projects; emphasis on "smart and wise" use of existing capacity.
  • No current plans for additional capital raising beyond the recent rights issue; company aims to be debt-free by FY '29.
  • Vizag facility mothballed; future use under strategic evaluation (options include potentially repositioning as multipurpose or high-potent API block).

2 more points from Solara Active Pharma Sciences Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Solara Active Pharma Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The base business of Solara has a very healthy order book, which is encouraging for sustained performance.
  • There is no specific quantitative figure disclosed for the current order book size.
  • The company is focused on expanding the existing business by seeding new customers for existing products, indicating ongoing and future orders.
  • CRAMS business remains subscale with annual revenues around INR 10-12 crores and lacks a strong order pipeline currently.
  • New product filings (4-5 DMFs annually) are planned, but meaningful revenue impact from these is expected around FY29-FY30.

2 more points from Solara Active Pharma Sciences Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Solara Active Pharma Sciences Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹417 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pha. (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn Ltd (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Solara Active Pharma Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Solara Active Pharma Sciences Ltd Q4 FY26 results?

The company expects growth momentum mainly from its base business, focusing on expanding existing products and customers rather than ibuprofen or CRAMS, which remain subscale. The company does not provide explicit future earnings or EPS guidance but expresses optimism about sustaining and improving current performance.

What is Solara Active Pharma Sciences Ltd share price analysis?

Solara Active Pharma Sciences Ltd currently shows a neutral. The stock trades at a P/E of 573.4 with a market cap of ₹2,448 Cr. Investors should review the full earnings analysis for detailed insights.

Is Solara Active Pharma Sciences Ltd planning capital expenditure?

No large greenfield capex planned; focus is on utilizing existing capacity (around 30% spare capacity available).

Keep Solara Active Pharma Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.